In the latest close session, Novavax (NVAX) was down 1.97% at $9.71. This change lagged the S&P 500's 0.55% gain on the day.

Novavax (NVAX) has become a focus for investors after signing a license agreement that allows Pfizer to use its Matrix-M ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 19.7% in the afternoon session after the company ...

Novavax Inc. (NASDAQ:NVAX) shares are up 3.3% to trade at $8.27 at last glance, after the vaccine company singed a licensing ...

Novavax (NVAX) stock jumps as the company announces a licensing deal with Pfizer (PFE) for its Matrix-M adjuvant. Read more here.

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine ...

Novavax (NASDAQ:NVAX) got a lift early Tuesday after the vaccine maker landed a licensing deal with Pfizer that puts its Matrix-M adjuvant to work in Pfizer's pipeline. Shares of Novavax were up about ...

Shares of US biotech Novavax were up 9% at $8.72 by midday on Tuesday, after it revealed it has entered into a license ...

Novavax, Inc. has entered into a license agreement with Pfizer for use of Novavax's Matrix-M® adjuvant. Under the terms of ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the ...